Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, has released the second annual Future Health Index. The study identifies a significant gap between healthcare professionals' and the general population's perceptions, and the reality of the readiness of health systems for the future. 
MAP Health Management and IBM (NYSE: IBM) Watson Health have announced a partnership that aims to address the pervasive problem of relapse among Americans suffering from Substance Use Disorder, a chronic disease. MAP will integrate Watson cognitive technologies into the MAP Recovery Network Platform to enhance the platform's existing capabilities around patient risk models. 
The WannaCry or WannaDecryptor virus was a world-wide phenomenon, but the NHS was badly hit. Dr Saif Abed, a founding partner of the health IT consultancy AbedGraham, says a forensic inquiry should be held into what went wrong; so the NHS can deal with the clinical and patient risk issues it exposed. 
SERMO, the largest global social network for physicians with 650,000 members worldwide, has announced the groundbreaking new "Drug Ratings" tool. Drug Ratings is the first and only global peer-to-peer prescription drug review system sourced exclusively from verified licensed physicians. With more than a quarter million ratings and 20,000 comments from doctors worldwide to date in the beta release, the Ratings platform is quickly becoming the largest global database of physician feedback on drugs. 
As a new member at Pistoia Alliance, Pryv joins with the mission to address the growing needs for improving the adoption of innovative technologies for patient and real-world data. Positioning itself as the next industry standard for personal and real-world data standard, Pryv is looking forward to participating in the Pistoia Alliance Community to promote collaboration as many organisations would benefit significantly from industry-wide pre-competitive collaboration. 
Abbott (NYSE: ABT) today announced CE Mark and first use of the new Confirm RxTM Insertable Cardiac Monitor (ICM), the world's first smartphone compatible ICM that will help physicians identify difficult to detect cardiac arrhythmias, including atrial fibrillation (AF), to help guide therapy. Since CE Mark approval, adoption of the device has been strong and implants have occurred in 10 countries across Europe. Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, is expanding Tasy, its award-winning next generation EMR solution, into the European market. The introduction is being marked with an agreement signed with KrankenHaus Düren. Together with this German public hospital, Philips will co-design and enterprise wide pilot Tasy.